PMID- 33100068
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 3
DP  - 2021 Mar
TI  - Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin 
      lymphoma.
PG  - 598-605
LID - 10.1080/10428194.2020.1837796 [doi]
AB  - Phosphoinositide-3-kinase (PI3K) inhibitors have efficacy in lymphoid 
      malignancies; however, inflammatory and infectious toxicities can compromise the 
      treatment course. An improved understanding of these toxicities will guide 
      clinical use and further development. We evaluated the occurrence of 
      treatment-related adverse events (AEs) in a retrospective review of 79 patients 
      treated in standard fashion with PI3K inhibitor monotherapy or with anti-CD20 
      monoclonal antibodies or as part of a novel combination regimen. Patients treated 
      with a novel combination were at a higher risk of developing a severe AE compared 
      to those treated with standard therapy (HR 1.89, 95% CI 1.02, 3.49; p = .04). 
      Additionally, previously untreated patients were at higher risk of developing a 
      severe AE compared to previously treated patients (HR 3.19, 95% CI 1.48, 6.84; 
      p = .003). These results caution against the use of untested PI3K inhibitor 
      combinations in routine practice and suggest that early phase clinical trials 
      should utilize conservative treatment schemas.
FAU - Rodgers, Thomas D
AU  - Rodgers TD
AUID- ORCID: 0000-0002-8937-8231
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Williams, AnnaLynn M
AU  - Williams AM
AUID- ORCID: 0000-0002-7042-5851
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Baran, Andrea
AU  - Baran A
AUID- ORCID: 0000-0002-7975-8919
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Reagan, Patrick M
AU  - Reagan PM
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Casulo, Carla
AU  - Casulo C
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Zent, Clive S
AU  - Zent CS
AUID- ORCID: 0000-0001-6099-3313
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Evans, Andrew
AU  - Evans A
AD  - Department of Pathology, University of Rochester Medical Center, Rochester, NY, 
      USA.
FAU - Friedberg, Jonathan W
AU  - Friedberg JW
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
FAU - Barr, Paul M
AU  - Barr PM
AUID- ORCID: 0000-0002-9733-401X
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, 
      Rochester, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20201025
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Phosphatidylinositol 3-Kinase
MH  - Phosphatidylinositol 3-Kinases/genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - PI3K inhibitor
OT  - adverse events
OT  - idelalisib
OT  - non-Hodgkin lymphoma
OT  - novel combinations
EDAT- 2020/10/27 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/26 05:16
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/10/26 05:16 [entrez]
AID - 10.1080/10428194.2020.1837796 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Mar;62(3):598-605. doi: 10.1080/10428194.2020.1837796. Epub 
      2020 Oct 25.